FDA Approves Johnson & Johnson Vaccine for Emergency Use Authorization

March 2, 2021

The U.S. Food and Drug Administration (FDA) approved a third COVID-19 vaccine last weekend. The agency’s approval quickly followed the Vaccines and Related Biological Products Advisory Committee’s vote to recommend the Johnson & Johnson vaccine for emergency use.

Clinical trials have indicated that a single dose of the Johnson & Johnson vaccine had an efficacy rate of up to 72%.
In late 2020, the Pfizer-BioNTech and the Moderna COVID-19 vaccines received FDA approval for emergency use. These companies are currently testing a third dose of their COVID-19 vaccine against new variants of the virus.

For information about other pandemic-related healthcare issues, access ISMIE’s COVID-19 resources for health professionals.
Share this article:

Cookie Consent

Cookies are required for some functionality on our site. View our privacy policy for more information.